Effective immediately, Evonik Industries is increasing the prices of its pharmaceutical amino acids. The increase, of between 10 and 15 percent depending on the amino acid and its quality, applies globally to all new orders and new supply agreements. The price increase is a result of the increased costs of raw materials and energy.
Evonik’s French subsidiary Rexim S.A.S. having production sites in Ham (France) and Nanning (China) is the world's third-largest supplier of amino acids and amino acid derivatives in pharmaceutical quality. These are used in the pharmaceutical industry for IV solutions and production of pharmaceutical active ingredients, such as those used to treat high blood pressure and diabetes, as well as in the cosmetics and food industries.
Evonik is the creative industrial group from Germany. In our core business of specialty chemicals, we are a global leader. In addition, it has energy and residential real estate operations. Our performance is shaped by creativity, specialization, reliability and continuous self-renewal.
Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.